Hadasit Bio-Holdings Ltd (HSITF)
USD 0.12
(0.0%)
USD 0.12
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.06 Million ILS | -79.3% |
| 2022 | 38.95 Million ILS | -41.35% |
| 2021 | 66.41 Million ILS | 60.5% |
| 2020 | 41.38 Million ILS | 339.65% |
| 2019 | 9.41 Million ILS | -73.36% |
| 2018 | 35.33 Million ILS | -48.49% |
| 2017 | 68.6 Million ILS | -1.23% |
| 2016 | 69.45 Million ILS | 1.23% |
| 2015 | 68.61 Million ILS | 111.64% |
| 2014 | 32.41 Million ILS | -6.73% |
| 2013 | 34.75 Million ILS | -19.52% |
| 2012 | 43.18 Million ILS | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 5.57 Million ILS | 0.0% |
| 2024 Q1 | 5.57 Million ILS | -30.89% |
| 2023 Q1 | 14.66 Million ILS | -62.34% |
| 2023 Q4 | 8.06 Million ILS | 0.0% |
| 2023 FY | 8.06 Million ILS | -79.3% |
| 2023 Q3 | 8.06 Million ILS | -45.02% |
| 2023 Q2 | 14.66 Million ILS | 0.0% |
| 2022 Q2 | 40.9 Million ILS | 0.0% |
| 2022 FY | 38.95 Million ILS | -41.35% |
| 2022 Q4 | 38.95 Million ILS | 0.0% |
| 2022 Q3 | 38.95 Million ILS | -4.77% |
| 2022 Q1 | 40.9 Million ILS | -38.41% |
| 2021 FY | 66.41 Million ILS | 60.5% |
| 2021 Q4 | 66.41 Million ILS | 0.0% |
| 2021 Q2 | 62.8 Million ILS | 0.0% |
| 2021 Q3 | 66.41 Million ILS | 5.74% |
| 2021 Q1 | 62.8 Million ILS | 51.78% |
| 2020 FY | 41.38 Million ILS | 339.65% |
| 2020 Q2 | 30.72 Million ILS | 0.0% |
| 2020 Q3 | 41.38 Million ILS | 34.7% |
| 2020 Q4 | 41.38 Million ILS | 0.0% |
| 2020 Q1 | 30.72 Million ILS | 226.4% |
| 2019 Q3 | 9.41 Million ILS | -46.91% |
| 2019 Q4 | 9.41 Million ILS | 0.0% |
| 2019 Q1 | 17.72 Million ILS | -49.83% |
| 2019 FY | 9.41 Million ILS | -73.36% |
| 2019 Q2 | 17.72 Million ILS | 0.0% |
| 2018 Q1 | 55.62 Million ILS | -18.91% |
| 2018 FY | 35.33 Million ILS | -48.49% |
| 2018 Q3 | 35.33 Million ILS | -36.48% |
| 2018 Q2 | 55.62 Million ILS | 0.0% |
| 2018 Q4 | 35.33 Million ILS | 0.0% |
| 2017 FY | 68.6 Million ILS | -1.23% |
| 2017 Q1 | 75.13 Million ILS | 8.17% |
| 2017 Q2 | 75.13 Million ILS | 0.0% |
| 2017 Q3 | 68.6 Million ILS | -8.69% |
| 2017 Q4 | 68.6 Million ILS | 0.0% |
| 2016 Q4 | 69.45 Million ILS | -2.91% |
| 2016 FY | 69.45 Million ILS | 1.23% |
| 2016 Q3 | 71.53 Million ILS | 1.8% |
| 2016 Q2 | 70.27 Million ILS | -1.71% |
| 2016 Q1 | 71.49 Million ILS | 4.21% |
| 2015 Q1 | 22.32 Million ILS | -31.14% |
| 2015 Q4 | 68.61 Million ILS | 262.57% |
| 2015 Q2 | 21.73 Million ILS | -2.65% |
| 2015 Q3 | 18.92 Million ILS | -12.92% |
| 2015 FY | 68.61 Million ILS | 111.64% |
| 2014 FY | 32.41 Million ILS | -6.73% |
| 2014 Q3 | 37.88 Million ILS | 14.15% |
| 2014 Q2 | 33.19 Million ILS | 3.32% |
| 2014 Q1 | 32.12 Million ILS | -7.58% |
| 2014 Q4 | 32.41 Million ILS | -14.43% |
| 2013 Q1 | 42.74 Million ILS | -1.04% |
| 2013 Q4 | 34.75 Million ILS | -16.82% |
| 2013 Q3 | 41.78 Million ILS | 7.63% |
| 2013 FY | 34.75 Million ILS | -19.52% |
| 2013 Q2 | 38.82 Million ILS | -9.16% |
| 2012 Q4 | 43.18 Million ILS | 0.0% |
| 2012 FY | 43.18 Million ILS | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -329.474% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1516.106% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2986.762% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 23.583% |
| GB Sciences, Inc. | 103.44 Thousand USD | -7696.64% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 9.88% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -45006.264% |
| Skye Bioscience, Inc. | 11.94 Million USD | 32.456% |
| Zenith Capital Corp. | 7410.00 USD | -108739.406% |
| Agentix Corp. | 261.39 Thousand USD | -2985.404% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -311.86% |
| Biomind Labs Inc. | 73.81 Thousand USD | -10825.372% |
| ContraFect Corporation | 20.67 Million USD | 60.999% |
| CSL Limited | 38.02 Billion USD | 99.979% |
| CytoDyn Inc. | 11.13 Million USD | 27.577% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -946.527% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 71.139% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1578.261% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -11044.89% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2180.716% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 93.806% |
| SQZ Biotechnologies Company | 107.18 Million USD | 92.476% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -143.434% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 79.239% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -463.186% |
| Mesoblast Limited | 667.9 Million USD | 98.792% |
| Marizyme, Inc. | 22.01 Million USD | 63.366% |
| Genus plc | 1.02 Billion USD | 99.216% |
| Pharming Group N.V. | 462.85 Million USD | 98.258% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1186.284% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2010.279% |
| IMV Inc. | 31.33 Million USD | 74.261% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -94.524% |
| MultiCell Technologies, Inc. | 126.22 USD | -6389537.141% |
| ONE Bio Corp. | 70.08 Million USD | 88.493% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 93.724% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 77.074% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -456.651% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 73.13% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -193.664% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1073.115% |
| Alpha Cognition Inc. | 2.45 Million USD | -228.892% |
| Enzolytics Inc. | 361.7 Million USD | 97.77% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.822% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 83.093% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1160.834% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.762% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -11.707% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -10462.642% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2406.168% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2985.735% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -769.11% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -493.734% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1966.01% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -758.263% |
| Helix BioMedix, Inc. | 3.02 Million USD | -166.604% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1768.135% |
| Q BioMed Inc. | 3.51 Million USD | -129.411% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 84.697% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.193% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 44.61% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -209.811% |
| HST Global, Inc. | 1526.00 USD | -528405.898% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -349034.199% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -716.323% |
| Halberd Corporation | 10.13 Thousand USD | -79507.146% |
| Resverlogix Corp. | 8.11 Million USD | 0.616% |
| Cell Source, Inc. | 195.17 Thousand USD | -4032.274% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -35302.309% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -9.324% |
| Ember Therapeutics, Inc. | 184.00 USD | -4383052.174% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -12856.24% |
| Kadimastem Ltd | 2.3 Million USD | -250.031% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -8331.166% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -14025.828% |
| LadRx Corporation | 2.3 Million USD | -249.455% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2180.716% |
| Affymax, Inc. | 7.44 Million USD | -8.357% |
| Itoco Inc. | 1.4 Million USD | -476.042% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -7508.491% |
| Mobile Lads Corp. | 52.00 USD | -15509515.385% |
| International Stem Cell Corporation | 5.39 Million USD | -49.629% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5759.574% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5540.965% |
| Qrons Inc. | 420.00 USD | -1920138.095% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1992.246% |
| SYBLEU INC | 330.46 Thousand USD | -2340.478% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1360.733% |
| Rebus Holdings, Inc. | 5000.00 USD | -161200.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1869.85% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 46.24% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 51.354% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -10108.861% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -832.718% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -7.29% |
| Neutra Corp. | 2851.00 USD | -282783.199% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 75.113% |
| PureTech Health plc | 693.97 Million USD | 98.838% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 0.075% |
| IXICO plc | 15.84 Million USD | 49.097% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 2.62% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.194% |
| CSL Limited | 38.02 Billion USD | 99.979% |
| Cellectis S.A. | 333.99 Million USD | 97.585% |